Compound Evidence File
#EC-2026-0466
TriTren 225
Filed under Injectable Oils. The bureau holds 109 laboratory returns for this compound from 46 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
46 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| WuXi TIDESCASE #VI-2026-0335 | A | 5 | 10.0 | 9.9 | 10.0 | 14 Apr 2026 | 24 Jul 2026 |
| HomopeptideCASE #VI-2026-0760 | A | 4 | 10.0 | 9.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 4 | 10.0 | 9.9 | 10.0 | 15 Dec 2025 | 5 Jul 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 2 | 10.0 | 10.0 | 10.0 | 27 Feb 2026 | 9 Jul 2026 |
| LipeptidesCASE #VI-2026-0863 | X | 1 | 10.0 | 10.0 | 10.0 | 24 Apr 2025 | 24 Apr 2025 |
| PeptiAtlasCASE #VI-2026-0739 | X | 1 | 10.0 | 10.0 | 10.0 | 24 Apr 2025 | 24 Apr 2025 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 7 | 9.9 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| BachemCASE #VI-2026-0314 | A | 4 | 9.9 | 9.9 | 10.0 | 22 Feb 2026 | 13 Jul 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 4 | 9.9 | 9.9 | 10.0 | 1 Apr 2026 | 12 Jul 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 4 | 9.9 | 9.9 | 10.0 | 24 Feb 2026 | 10 Jul 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 4 | 9.9 | 9.9 | 10.0 | 10 Apr 2026 | 5 Jul 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 3 | 9.9 | 9.9 | 10.0 | 15 Apr 2026 | 3 Jun 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 3 | 9.9 | 9.9 | 9.9 | 5 Mar 2026 | 17 May 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 2 | 9.9 | 9.9 | 10.0 | 7 Nov 2025 | 13 Jun 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 2 | 9.9 | 9.9 | 9.9 | 3 May 2026 | 20 May 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 2 | 9.9 | 9.9 | 10.0 | 8 Jun 2026 | 15 Jun 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 2 | 9.9 | 9.9 | 9.9 | 23 Jun 2026 | 9 Jul 2026 |
| Lisa BiopeptideCASE #VI-2026-0131 | X | 1 | 9.4 | 9.4 | 9.4 | 2 Jul 2025 | 2 Jul 2025 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 4 | 9.1 | 8.7 | 10.0 | 24 May 2026 | 24 May 2026 |
| Lux Synth AminosCASE #VI-2026-0700 | X | 1 | 9.0 | 9.0 | 9.0 | 7 May 2025 | 7 May 2025 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 2 | 8.9 | 8.8 | 9.1 | 24 May 2026 | 24 May 2026 |
| Paradigm PeptideCASE #VI-2026-0759 | X | 1 | 8.9 | 8.9 | 8.9 | 14 Jan 2025 | 14 Jan 2025 |
| Bfflist AMOCASE #VI-2026-0678 | X | 4 | 8.8 | 6.7 | 9.9 | 13 Jun 2025 | 24 May 2026 |
| NUPEPS PeptidesCASE #VI-2026-0896 | X | 1 | 8.4 | 8.4 | 8.4 | 21 May 2025 | 21 May 2025 |
| Hunan Ruiwang Technology CenterCASE #VI-2026-0027 | X | 1 | 8.3 | 8.3 | 8.3 | 3 Jun 2025 | 3 Jun 2025 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 7 | 8.2 | 6.9 | 9.1 | 24 May 2026 | 24 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 2 | 8.2 | 7.8 | 8.6 | 24 May 2026 | 24 May 2026 |
| Haikou Mingheng TechnologyCASE #VI-2026-0250 | X | 1 | 8.2 | 8.2 | 8.2 | 16 Mar 2025 | 16 Mar 2025 |
| AKS ChemCASE #VI-2026-0313 | X | 1 | 8.1 | 8.1 | 8.1 | 20 Jun 2025 | 20 Jun 2025 |
| Pure Tested PeptidesCASE #VI-2026-0225 | X | 1 | 7.8 | 7.8 | 7.8 | 14 Jan 2025 | 14 Jan 2025 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 4 | 7.5 | 6.0 | 8.6 | 24 May 2026 | 24 May 2026 |
| Shanghai JinBei Chemical TechnologyCASE #VI-2026-0107 | X | 1 | 7.3 | 7.3 | 7.3 | 20 Jun 2025 | 20 Jun 2025 |
| HealthTide BiotechCASE #VI-2026-0955 | X | 1 | 7.1 | 7.1 | 7.1 | 27 Feb 2025 | 27 Feb 2025 |
| Golden EagleCASE #VI-2026-0680 | X | 1 | 6.9 | 6.9 | 6.9 | 3 Jul 2025 | 3 Jul 2025 |
| Reta-PeptideCASE #VI-2026-0756 | X | 2 | 6.8 | 6.6 | 7.1 | 3 Jun 2025 | 20 May 2026 |
| Glamgurcraft Innovations Foreign TradeCASE #VI-2026-0348 | X | 1 | 6.7 | 6.7 | 6.7 | 14 Jan 2025 | 14 Jan 2025 |
| ZLZ PeptideCASE #VI-2026-0524 | X | 6 | 6.5 | 5.3 | 8.3 | 2 Jul 2025 | 25 May 2026 |
| Shanghai Leader Peptide BiotechnologyCASE #VI-2026-0558 | X | 1 | 6.3 | 6.3 | 6.3 | 8 Jul 2025 | 8 Jul 2025 |
| Haikou Mingheng BiotechnologyCASE #VI-2026-0126 | X | 1 | 6.2 | 6.2 | 6.2 | 13 Feb 2025 | 13 Feb 2025 |
| HybiopeptidesCASE #VI-2026-0305 | X | 1 | 6.1 | 6.1 | 6.1 | 14 Jan 2025 | 14 Jan 2025 |
| Shanghai BaojuCASE #VI-2026-0233 | X | 2 | 5.9 | 4.3 | 7.6 | 25 Apr 2025 | 19 Jan 2026 |
| Polaris PeptidesCASE #VI-2026-0839 | X | 2 | 5.4 | 5.3 | 5.6 | 24 Apr 2025 | 21 May 2026 |
| Simple PeptideCASE #VI-2026-0782 | X | 2 | 5.2 | 4.6 | 5.7 | 13 Jun 2025 | 24 May 2026 |
| Guangzhou Lengiuanhuang CosmeticsCASE #VI-2026-0228 | X | 1 | 3.2 | 3.2 | 3.2 | 16 Mar 2025 | 16 Mar 2025 |
| LOOKBiotechCASE #VI-2026-0807 | X | 1 | 0.0 | 0.0 | 0.0 | 3 Jun 2025 | 3 Jun 2025 |
| Advanced Technology and IndustrialCASE #VI-2026-0133 | X | 1 | 0.0 | 0.0 | 0.0 | 7 May 2025 | 7 May 2025 |
Open any subject to view the batch-level evidence for TriTren 225 alone.